Actively Recruiting

Age: 18Years +
All Genders
ID06797752

Effect of the Stellate Ganglion Block on the Retinal Microcirculation: A Pilot Study

Led by University of Texas Southwestern Medical Center · Updated on 2025-11-19

50

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating the effects of the stellate ganglion nerve block on retinal microcirculation in patients with neurological critical illnesses such as intracranial hemorrhage and subarachnoid hemorrhage. These conditions often cause surges in the sympathetic nervous system that may lead to secondary brain injury through mechanisms like diffuse vasospasm and cerebral ischemia. The study aims to understand how blocking the sympathetic nervous system might influence microcirculation in the eye. Participants in this observational study will receive the stellate ganglion nerve block as part of their standard medical care. The key procedure involves imaging the retinal microcirculation using Optical Coherence Tomography Angiography (OCTA) before and after the nerve block. This technique is known to reduce cerebral sympathetic activity and vasospasm, and the study will assess its impact on retinal blood vessel density and perfusion. During the study, participants will undergo OCTA scans to measure vascular and perfusion density one day after the procedure. Researchers will monitor these changes to evaluate the nerve block's effect on retinal microcirculation. The study is sponsored by the University of Texas Southwestern Medical Center and will include adult patients receiving this nerve block for approved conditions. Participation involves imaging and standard care without additional interventions, and the study is expected to conclude by October 2026.

CONDITIONS

Brief Title

Effect of the Stellate Ganglion Block on the Retinal Microcirculation

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Patients receiving the stellate ganglion nerve block for an approved indication, e.g. complex regional pain syndrome
Not Eligible

You will not qualify if you...

  • Pregnancy
  • Non-English speaking
  • Temporary or permanent physical limitation that renders the patient unable to sit up and look inside OCTA device

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - 1 day

Participants undergo Optical Coherence Tomography Angiography scans before and after receiving the stellate ganglion nerve block.

2 visits (in-person)

Trial Site Locations

Total: 1 location

1

UT Southwestern Medical Center

Dallas, Texas, United States, 75235

Actively Recruiting

Loading map...

Research Team

N

Noah Jouett, DO, PhD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Pilot Study of 3D Ultrasound Localization Microscopy to Dete...

Subarachnoid Hemorrhage

Actively Recruiting

1 location

A Pilot Trial of a Disposable Intracerebral Aspiration Endos...

Intracerebral Hemorrhage

Actively Recruiting

1 location

Use of Active Fluid Exchange to Therapeutically Treat Intrac...

Intraventricular Hemorrhage

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures.

Niall Patton, Tariq Aslam, Thomas Macgillivray...

https://pubmed.ncbi.nlm.nih.gov/15817102